NCT03225027 (SKYPROVERB) is a NA clinical trial of Emotional judgment task in Schizophrenia Simple, sponsored by Hôpital NOVO.

Who is sponsoring NCT03225027?

NCT03225027 is sponsored by Hôpital NOVO.

What drugs are being tested in NCT03225027?

Interventions in NCT03225027: Emotional judgment task, Post-experimental questionnaire, Recognition task, Detection task, CAPE-42, Trait Emotional Intelligence Questionnaire, Positive And Negative Syndrome Scale, Mini International Neuropsychiatric Interview.

What condition does NCT03225027 study?

NCT03225027 studies Schizophrenia Simple.

Is NCT03225027 still recruiting?

NCT03225027 is currently completed. Last updated 29 July 2019.

Last reviewed 2019-07-29 · How we verify

NCT03225027: SKYPROVERB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Communication Comprehension in the Schizophrenic Spectrum

Completed NA Last updated 29 July 2019

What this trial tests

NA trial testing Emotional judgment task in Schizophrenia Simple in 59 participants. Completed in 27 May 2019.

Timeline

15 November 2016

Primary endpoint
27 May 2019

27 May 2019

Quick facts

Lead sponsor	Hôpital NOVO
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	59
Start date	15 November 2016
Primary completion	27 May 2019
Estimated completion	27 May 2019
Sites	1 location across France

Drugs / interventions tested

Emotional judgment task
Post-experimental questionnaire
Recognition task
Detection task
CAPE-42
Trait Emotional Intelligence Questionnaire
Positive And Negative Syndrome Scale
Mini International Neuropsychiatric Interview

Conditions studied

Schizophrenia Simple — all drugs for Schizophrenia Simple →

Sponsor

Hôpital NOVO — full company profile →

Who can join

Adults 18 to 60, any sex, with Schizophrenia Simple. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study is to evaluate the effect of emotional prosody on the perception of emotional discourse in the schizophrenic spectrum. The investigators hypothesize that participant may use emotional prosody as an emotional cue to understand the emotional content of discourse.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hôpital NOVO trials

Trials by the same sponsor.

NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03225027 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
Last refreshed: 29 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03225027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing